Top-News

NanoViricides News

Keine aktuellen Kursdaten verfügbar
WKN: A1W477
ISIN: US6300872032
Typ: Aktie

NanoViricides News

27.10.22 - DGAP
EQS-News: This Company Is Looking For A Monkeypox Drug As City Investigates Deaths
EQS-News: NanoViricides, Inc. This Company Is Looking For A Monkeypox Drug As City Investigates Deaths 27.10.2022 / 15:25 CET/CEST The issuer is solely responsible for the ...
19.09.22 - DGAP
EQS-News: NanoViricides Reports Its Novel Monkeypox Antiviral Could Reach Clinical Status Rapidly
EQS-News: NanoViricides, Inc. NanoViricides Reports Its Novel Monkeypox Antiviral Could Reach Clinical Status Rapidly 19.09.2022 / 15:26 CET/CEST The issuer is solely ...
10.08.22 - DGAP
Monkeypox Is Popping Up In Places It Shouldn’t But NanoViricides Says It May Have A Solution
DGAP-News: NanoViricides, Inc. Monkeypox Is Popping Up In Places It Shouldn’t But NanoViricides Says It May Have A Solution 10.08.2022 / 14:00 The issuer is solely responsible ...
16.05.22 - ACCESSWIRE
NanoViricides Reports that It Has Begun Drug Development to Combat Recent Cases of Severe Pediatric Hepatitis
SHELTON, CT / ACCESSWIRE / May 16, 2022 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company") a global leader in the development of highly effective antiviral therapies ...
25.04.22 - ACCESSWIRE
NanoViricides Provides Update On NV-CoV-2 Coronavirus Drug Candidate Program
SHELTON, CT / ACCESSWIRE / April 25, 2022 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company") a global leader in the development of highly effective antiviral therapies ...
15.02.22 - ACCESSWIRE
NanoViricides Has Filed Quarterly Report for Period Ending December 31, 2021 - Has Sufficient Cash, NV-CoV-2 Coronavirus Drug Candidate Clinical Trials Application Ready
SHELTON, CT / ACCESSWIRE / February 15, 2022 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company") a global leader in the development of highly effective antiviral ...
16.11.21 - ACCESSWIRE
NanoViricides Has Filed Quarterly Report for Period Ending September 30, 2021 - Has Sufficient Cash, Coronavirus Drug Candidate Moving Towards Clinical Trials
SHELTON, CT / ACCESSWIRE / November 16, 2021 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company") a global leader in the development of highly effective antiviral ...
15.11.21 - ACCESSWIRE
NanoViricides Completes Oral Gummies and Lung Inhalation Formulations Development for its Non-Mutagenic, Safe, Broad-Spectrum COVID-19 Clinical Drug Candidate, NV-CoV-2
SHELTON, CT / ACCESSWIRE / November 15, 2021 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies ...
13.10.21 - ACCESSWIRE
NanoViricides, Inc. Has Filed its Annual Report: Coronavirus Drug Program Rapidly Moving Towards Clinical Stage
SHELTON, CT / ACCESSWIRE / October 13, 2021 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Annual Report on Form 10-K for the fiscal ...
11.10.21 - ACCESSWIRE
NanoViricides Announces COVID-19 Clinical Drug Candidate NV-CoV-2 was Effective Against SARS-CoV-2, Further Demonstrating Its Broad-Spectrum Pan-Coronavirus Activity
SHELTON, CT / ACCESSWIRE / October 11, 2021 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies ...
17.05.21 - ACCESSWIRE
NanoViricides Has Filed Quarterly Report for Period Ending March 31, 2021 - Has Sufficient Cash, Coronavirus Drug Candidate Moving Towards IND
SHELTON, CT / ACCESSWIRE / May 17, 2021 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company") a global leader in the development of highly effective antiviral therapies ...
09.03.21 - ACCESSWIRE
NanoViricides, Inc. Pan-coronavirus COVID-19 Drug Candidates Are Highly Effective in Pre-clinical Animal Studies in Support of FDA Pre-IND Application
SHELTON, CT / ACCESSWIRE /  March 9, 2021 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a leader in the development of highly effective antiviral therapies ...
02.03.21 - ACCESSWIRE
NanoViricides, Inc. Pan-coronavirus Clinical Drug Candidates for the Treatment of COVID-19 Are Highly Effective in Pre-clinical Cell Culture Studies Performed in Preparation of FDA Pre-IND Application
SHELTON, CT / ACCESSWIRE / March 2, 2021 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company") a leader in the development of highly effective antiviral therapies ...
17.02.21 - ACCESSWIRE
NanoViricides Has Filed Quarterly Report for Period Ending December 31, 2020 - Has Sufficient Cash, Coronavirus Drug Candidate Safe in GLP Safety Toxicology Moving Towards IND
SHELTON, CT / ACCESSWIRE / February 17, 2021 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company") a global leader in the development of highly effective antiviral ...
08.02.21 - ACCESSWIRE
NanoViricides’s Broad-Spectrum Antiviral Drug Candidate for the Treatment of COVID-19 Infections was Well Tolerated in GLP and non-GLP Animal Safety Studies
SHELTON, CT / ACCESSWIRE / February 8, 2021 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company") a global leader in the development of highly effective broad-...
27.01.21 - ACCESSWIRE
Broad-Spectrum Direct Antiviral Nanomedicine Should Remain Effective Against COVID-19 Virus Variants, Says NanoViricides, Inc.’s President, Dr. Anil Diwan
SHELTON, CT / ACCESSWIRE / January 27, 2021 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company") a global leader in the development of highly effective broad-...
19.11.20 - ACCESSWIRE
NanoViricides Strengthens its Board of Directors with Addition of Industry Veteran Brian Zucker, CPA
SHELTON, CT / ACCESSWIRE / November 19, 2020 / NanoViricides, Inc. (NYSE Amer.: NNVC ) (the "Company"), a leader in developing novel nanomedicines to treat viral diseases, ...
17.11.20 - ACCESSWIRE
NanoViricides Has Filed Quarterly Report for Period Ending September 30, 2020 - Has Sufficient Cash, Coronavirus Drug Development Progress
SHELTON, CT / ACCESSWIRE / November 17, 2020 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company") a global leader in the development of highly effective antiviral ...
11.11.20 - ACCESSWIRE
NanoViricides Has Engaged Calvert Labs for Safety Pharmacology Studies of Its Drug for the Treatment of COVID-19
SHELTON, CT / ACCESSWIRE / November 11, 2020 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company") a global leader in the development of highly effective antiviral ...
15.10.20 - ACCESSWIRE
NanoViricides, Inc. Has Filed its Annual Report: Strengthened Financial Position and Rapidly Developing Novel Coronavirus Drug Program
SHELTON, CT / ACCESSWIRE / October 15, 2020 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), reports that it has filed its Annual Report on Form 10-K for the ...

Newssuche

Videos

24.04.24
Technical Trading: AUD/USD mit Mega Chance
AUD/USD Long Typ: Turbo Open End WKN: UM0EHU Hebel: 6,42 Laufzeit: OpenEnd Einstieg: Market ... Mehr »